The extent and biological impact of RNA cytosine methylation are poorly understood, in part owing to limitations of current techniques for determining the targets of RNA methyltransferases. Here we describe 5-azacytidine-mediated RNA immunoprecipitation (Aza-IP), a technique that exploits the covalent bond formed between an RNA methyltransferase and the cytidine analog 5-azacytidine to recover RNA targets by immunoprecipitation. Targets are subsequently identified by high-throughput sequencing. When applied in a human cell line to the RNA methyltransferases DNMT2 and NSUN2, Aza-IP enabled >200-fold enrichment of tRNAs that are known targets of the enzymes. In addition, it revealed many tRNA and noncoding RNA targets not previously associated with NSUN2. Notably, we observed a high frequency of C→G transversions at the cytosine residues targeted by both enzymes, allowing identification of the specific methylated cytosine(s) in target RNAs. Given the mechanistic similarity of RNA cytosine methyltransferases, Aza-IP may be generally applicable for target identification.
l e t t e r s
The extent and biological impact of RNA cytosine methylation are poorly understood, in part owing to limitations of current techniques for determining the targets of RNA methyltransferases. Here we describe 5-azacytidine-mediated RNA immunoprecipitation (Aza-IP), a technique that exploits the covalent bond formed between an RNA methyltransferase and the cytidine analog 5-azacytidine to recover RNA targets by immunoprecipitation. Targets are subsequently identified by high-throughput sequencing. When applied in a human cell line to the RNA methyltransferases DNMT2 and NSUN2, Aza-IP enabled >200-fold enrichment of tRNAs that are known targets of the enzymes. In addition, it revealed many tRNA and noncoding RNA targets not previously associated with NSUN2. Notably, we observed a high frequency of C→G transversions at the cytosine residues targeted by both enzymes, allowing identification of the specific methylated cytosine(s) in target RNAs. Given the mechanistic similarity of RNA cytosine methyltransferases, Aza-IP may be generally applicable for target identification.
Although cytosine methylation is most commonly studied in DNA, it is also found in RNA 1 . As with DNA, RNA cytosine methylation occurs at the C5 position (m 5 C). RNA methylation has been detected in both prokaryotic and eukaryotic noncoding RNAs (ncRNAs) such as tRNA and rRNA 1 . Recent high-throughput RNA methylation profiling by bisulfite sequencing in HeLa cells verified and extended the repertoire of m 5 C modifications in RNA 2 , motivating a more thorough examination of the scope (cell types and developmental contexts) and functions of RNA methylation.
The m 5 C-RNA methyltransferases have been subdivided into six families based on structural and functional properties: RsmB/Nol1/ NSUN1, RsmF/YebU/NSUN2, RlmI, Ynl022, NSUN6 and DNMT2 (ref. 1) . Only DNMT2-family enzymes are of the single-cysteine type; similar to DNA methyltransferases, they utilize a single cysteine in their catalytic pocket 3 , whereas the other m 5 C-RNA methyltransferase family enzymes utilize two cysteines 4 . Here we focus on DNMT2 and NSUN2, as they represent one member of each family that is either highly studied (DNMT2) or highly relevant to a specific disease (NSUN2).
DNMT2 functions primarily, if not exclusively, as an m 5 C-RNA methyltransferase, with three verified tRNA targets: tRNA Asp , tRNA Gly and tRNA Val (refs. 3,5-7) . In most organisms, lack of DNMT2 is not phenotypically evident 8 , although DNMT2-deficient zebrafish display developmental perturbations 6 . Notably, DNMT2 activity attenuates tRNA cleavage during stress conditions, and promotes response to RNA viruses in Drosophila 7, 9 . NSUN2 also methylates cytosines in tRNAs as well as in the ncRNA subunit of RNase P and possibly mRNA substrates 2, 10, 11 , but the links between particular NSUN2 targets and cellular functions are unknown. NSUN2 has been associated with Myc-induced proliferation of cancer cells 12 , mitotic spindle stability 13 , infertility in male mice, and the balance of self-renewal and differentiation in skin stem cells 14 . In humans NSUN2 mutations cause an autosomal recessive syndrome characterized by intellectual disability and mental retardation [15] [16] [17] . Furthermore, tRNA cytosine methylation by both Dnmt2 and Nsun2 in mice increases tRNA stability and steady-state protein synthesis 10 .
In principle, RNA targets of m 5 C-RNA methyltransferases could be identified by deep RNA bisulfite sequencing of cell lines or tissues in which a particular m 5 C-RNA methyltransferase has been knocked down or knocked out 2 . However, this approach is labor intensive and requires effective enzyme knockout methods. In addition, in cases in which other enzymes are redundant with the m 5 C-RNA methyltransferase under study, targets of interest may be missed. Although such an approach could identify candidate targets of the m 5 C-RNA methyltransferase, it could not distinguish between direct and indirect targets. Lastly, this approach would require extremely deep sequencing to reveal modifications on RNAs of low abundance or low methylation penetrance. To circumvent these and other issues, we developed Aza-IP, a technique that enriches the direct RNA targets of specific m 5 C-RNA methyltransferases and identifies the precise cytosine(s) targeted by the enzyme.
Like m 5 C-DNA methyltransferases all m 5 C-RNA methyltransferases tested to date form a covalent enzyme-substrate intermediate with their target 1 . Specifically, the sulfur atom of a cysteine residue in the m 5 C-RNA methyltransferase catalytic domain covalently bonds to the C6 position of the base in the target RNA. Covalent linkage precedes methylation, which occurs by enamine methylation of the C5 position of the target cytosine using the methyl donor S-adenosyl methionine (SAM). Free enzyme is regenerated by subsequent beta elimination 1 (Fig. 1a) .
This catalytic mechanism is disrupted by the suicide inhibitors 5-azacytidine (5-aza-C) and 5-aza-2′-deoxycytidine (5-aza-dC) 18 . These cytidine analogs are randomly incorporated by RNA and Identification of direct targets and modified bases of rNA cytosine methyltransferases l e t t e r s DNA polymerases into nascent RNA or DNA molecules, respectively. Owing to nitrogen substitution at C5, RNA and DNA methyltransferase enzymes remain covalently bound to the target RNA or DNA molecule ( Fig. 1b) , thereby depleting cells of the endogenous enzymes and resulting in hypomethylation of RNA and DNA [18] [19] [20] [21] . Thus, in the presence of 5-aza-C, even overexpression of an m 5 C-RNA methyltransferase should result in only a small amount of short-lived free active enzyme, greatly reducing concern that enzyme overexpression will result in the methylation of nonphysiological, irrelevant targets. Given their effectiveness in enzyme depletion, 5-aza-C and 5-aza-dC are currently used for a variety of experimental and clinical applications, including linkage of a DNMT to a known target DNA in vivo 22 , visualization and monitoring of DNMTs in living cells 23 , and inducing DNA hypomethylation of tumor cells in patients 24 .
Aza-IP involves nine steps: (i) expression of an epitope-tagged m 5 C-RNA methyltransferase derivative in cells (or use of an antibody capable of immunoprecipitating the endogenous RNA-bound enzyme); (ii) cell growth in the presence of 5-aza-C, which is incorporated at low or moderate levels into nascent RNA; (iii) cell lysis; (iv) immunoprecipitation of the m 5 C-RNA methyltransferase of interest, a portion of which is covalently attached to target RNAs bearing 5-aza-C; (v) stringent washing to remove RNA contaminants; (vi) RNA fragmentation, release and purification; (vii) ligation of adaptor oligos to the RNA, and creation of a cDNA library in a manner that enables strand-specific assignments; (viii) cDNA sequencing (50-bp single end); (ix) mapping and analysis of sequence reads to define RNA targets and site of cross-linking and/or catalysis ( Fig. 1c and Online Methods).
We chose HeLa cells because of their favorable growth properties and ease of infection by lentiviruses. We overexpressed V5-tagged (epitope derived from simian virus 5) human DNMT2 (test) or V5tagged DsRed (control) proteins using a lentiviral expression system and the relatively strong cytomegalovirus (CMV) immediate early promoter. We grew HeLa cells in 3 µM 5-aza-C for a time (12 h) empirically determined as sufficient for incorporation of 5-aza-C into nascent RNA and efficient RNA target detection (3-5 µM 5-aza-C facilitates 5-aza-C incorporation without detectable toxicity, and 6-to 24-h time ranges should be tested). Cells were lysed in a stringent denaturing buffer supplemented with an RNase inhibitor, briefly sonicated and cleared to yield a cell lysate. The lysate was incubated with magnetic beads coated with anti-V5, and the beads were stringently washed, taking advantage of the covalent association between DNMT2 and target RNA. We then fragmented the enriched RNA molecules while they were still bound to the beads, generating RNA fragments of appropriate size (60-200 bp) for the construction of sequencing libraries. These RNA fragments were then isolated, ethanol precipitated and extracted. RNA samples were then used for directional (strand-specific) cDNA library preparation and, after application of quality control procedures, the cDNA library was subjected to highthroughput sequencing using Illumina 50-bp single-end sequencing (Online Methods).
We used the USeq analysis package and Biotoolbox to identify RNAs showing statistically significant enrichment in DNMT2 immunoprecipitates (Online Methods). The known DNMT2 targets (tRNA Asp , tRNA Gly and tRNA Val ) 7 were detected at background levels in the control V5-DsRed immunoprecipitates, but were markedly enriched 271-, 431-and 255-fold, respectively, compared to V5-DsRed control in the V5-DNMT2 immunoprecipitates ( Fig. 2a,b and Supplementary Data set 1). It appeared that DNMT2 was indeed released from the target 5-aza-C base during the fragmentation step, as sequence reads covering the known target cytosine (C38) were plentiful and not depleted relative to reads covering the flanking sequences. Beyond these three tRNAs, we found no comparable enrichment of other ncRNAs (rRNAs, small nuclear RNAs, small nucleolar RNAs, small cytoplasmic RNAs, microRNAs) or mRNAs, with two preliminary exceptions; the KRT18 mRNA and the KRT18 pseudogene mRNA displayed moderate enrichment and a C→G transversion (a purine replacement of a pyrimidine, explained below) (Supplementary Data set 2 and Supplementary Fig. 1 ). Although we did not rigorously l e t t e r s validate these mRNA enrichments in vivo, we instead used KRT18 RNA fragments and tRNAs to reveal that DNMT2 activity requires a CpG within a tRNA-type stem-loop junction ( Supplementary  Result 1 and Supplementary Figs. 2-7) . Together, these findings indicate that Aza-IP highly enriched only the three known tRNA targets of DNMT2.
Notably, a majority of the reads that mapped to the three known target tRNAs contained a single-nucleotide polymorphism (SNP) present solely at the known DNMT2 target cytosine (C38) ( Fig. 2c-e and Supplementary Data set 1). Typically, the base change involved transversion to guanosine; however, adenosine and thymine were also observed at levels well above the estimated error rate of sequencing (~0.5%). Transversion was observed at the target cytosine but almost never (<1%) at other cytosines in all three DNMT2 target tRNAs. Over 200 m 5 C sites have been identified in different human tRNAs and their isoacceptors or isodecoders 2 (tRNAs that accept the same amino acid but have different anticodons, or have identical anticodons but different body sequences, respectively). However, only C38 and not the other sites bearing m 5 C in these three tRNAs exhibited transversion in our data sets. Thus, Aza-IP does not simply cause mutations at cytosines, or at m 5 C; rather, transversion is observed specifically at DNMT2 target sites in the RNA enriched by our technique. These are true transversions, not SNPs, because standard high-throughput RNA sequencing profiles from HeLa cells revealed cytosine at C38 in >99% of the reads (data not shown). Notably, previous work with DNMTs revealed C→G transversion occurring within DNA following the growth of cells in 5-aza-C; the authors proposed that covalent attachment of the DNMT to the target 5-aza-C enables the opening of the 5-aza-C ring and its subsequent pairing with cytosine at replication 25 (Fig. 2f,g) .
To validate the DNMT2 targets identified by Aza-IP, we performed transcriptome-wide RNA bisulfite sequencing in wild-type (WT) and Dnmt2-knockout mouse embryonic fibroblasts (MEFs); we used MEFs because knockdown of DNMT2 in HeLa could not be validated with current antibodies. We adapted existing methods and criteria (coverage >10 reads, methylation level >20%) 2 , defined the significantly methylated cytosines, and compared the WT and Dnmt2-knockout data sets (Supplementary Data set 3) . In Dnmt2knockout but not WT MEFs, we observed a total loss of RNA methylation at the three known DNMT2 tRNA targets identified by Aza-IP; 25 npg l e t t e r s other sites of RNA methylation were not affected. However, the site of methylation observed in human KRT18 mRNA is not conserved in the mouse Krt18 mRNA. We then applied Aza-IP to identify RNA targets of the 'two cysteine' human enzyme NSUN2. Previous studies identified three direct tRNA targets of human NSUN2 (tRNA Leu (C34), tRNA Asp (C48, 49) and tRNA Gly (C48, 49, 50)) 2,11,26 , four direct tRNA targets of mouse Nsun2 (tRNA Leu (C34); tRNA Asp (C48, 49), tRNA Gly (C40, 48, 49, 50) and tRNA Val (C48, 49)) 10 , and seven additional target cytosines in the tRNA targets for yeast Trm4/Nsun2 (refs. 27,28) ( Fig. 3 and Supplementary Fig. 8) .
We expressed V5-NSUN2 (with modifications; see Online Methods) in HeLa cells, and performed two anti-V5 biological replicates (Rep1 and Rep2), and one IgG-only (control) replicate, of Aza-IP. Rep1, Rep2 and IgG-only experiments yielded 55,180,207, 56,051,845 and 57,133,775 mapped filtered reads, respectively.
We applied three criteria for identifying candidate NSUN2 RNA targets: reads per kilobase per million mapped reads (RPKM > 3); enrichment (replicates RPKM/control RPKM over threefold and falsediscovery rate (FDR) < 0.01); and transversion frequency (>4%, and P < 0.01). Our mapping and analyses enabled attribution of reads to tRNA Gly(GCC) 38 40 48 49 50 npg l e t t e r s particular isoacceptors and/or isodecoders (Supplementary Data  set 4) , and we provide in Supplementary Data set 5 the precise human genome coordinate (hg19) of the methylated cytosine and P values for transversion. Almost all tRNAs were enriched in both replicates of anti-V5-NSUN2 immunoprecipitates (tRNA Asn and tRNA SeC excepted), with many enriched over 100-fold (Fig. 3a) . The diversity of candidate NSUN2 RNA targets and candidate target sites required a rigorous statistical approach. Therefore, we used VarScan, a package for analyzing sequence variants in parallel sequencing data, to define locations where C→G transversions were both frequent (≥4%) and highly significant (P < 0.01) in both anti-V5-NSUN2 replicates, but not in the IgG-only control. We also applied VarScan to RNA-seq data sets of HeLa cells, to filter out SNPs. Transversion was clear and significant ( Fig. 3b and Supplementary Data set 5) at the known human NSUN2 tRNA targets (tRNA Leu (C34), tRNA Asp (C48, 49) and tRNA Gly (C48, 49, 50)) 2,11,26 , as well as at C48, C49 and C50 within most tRNAs (tRNA Asn and tRNA SeC excepted), greatly expanding the known repertoire. Importantly, although the target tRNAs of DNMT2 were robustly enriched within anti-V5-NSUN2 immunoprecipitates, we did not observe C→G transversion at the DNMT2 target site (C38) within the anti-V5-NSUN2 immunoprecipitates, highlighting the specificity of both the enzyme and the Aza-IP technique (Fig. 3c,d) . Furthermore, we identified a large number of additional candidate NSUN2 target sites within particular tRNAs; these sites were not previously described in any organism (P < 0.01) ( Fig. 3b and Supplementary Data set 5) .
Moreover, we observed significant transversion sites within introns, and also upstream and downstream, of particular preprocessed tRNAs (P < 0.01) ( Fig. 3b and Supplementary Data set 5) .
Notably, within a particular RNA, the extent of C→G transversion was proportionally lower when there were multiple target sites. For example, tRNA Gly(GCC) bears one DNMT2 target site (C38) and four NSUN2 target sites (C40, 48, 49, 50) ( Fig. 3d) ; here, the transversion frequency at C38 with DNMT2 was comparable to the sum at the four NSUN2 target sites ( Fig. 3c and Supplementary Fig. 9 ), consistent with covalent linkage of the m 5 C-RNA methyltransferase to only one target site in any individual isolated tRNA.
Human NSUN2 has been reported to methylate cytosines in four other RNAs: ribosomal RNA 12 , the RNA subunit of RNaseP (RPPH1) (c) Extracts (60 µg of protein was loaded on the gel) of HeLa cells expressing NSUN2 or nonspecific (control) siRNA pools were probed with anti-hNSUN2 or anti-vinculin (control) ( Supplementary Fig. 10 ). (d) Total RNA was extracted from HeLa cells treated with NSUN2 or control siRNAs; RNA was subjected to bisulfite treatment, PCR amplification, cloning and sequencing of several clones per sample (Online Methods). Candidate target sites of NSUN2 (in red; C178 in RPPH1, C316 in SCARNA2, C70 in VTRNA1-1, and C40, C48, C49 and C50 in tRNA Gly(GCC) ) and DNMT2 (in blue; C38 in tRNA Gly(GCC) ) were analyzed. l e t t e r s and two mRNAs (CINP and NAPRT1) 2 . Our Aza-IP analyses yielded eight candidate NSUN2 target ncRNAs: 5S rRNA, RPPH1, vault RNAs (VTRNA1-1, VTRNA1-3 and VTRNA2-1), the small cajal bodyspecific RNA 2 (SCARNA2, a C/D box snoRNA), a Y RNA (RNY1) and the signal recognition particle RNA (7SL RNA) ( Fig. 4a) . All of these RNAs contain one very clear and significant target site (Fig. 4b) , and most contain one or more additional sites that also pass all three thresholds in both anti-V5-NSUN2 replicates but not the IgG-only control (Supplementary Data set 5) ; these findings suggest that, as with tRNAs, most ncRNA targets have more than one NSUN2 target cytosine. Notably, Aza-IP analysis did not detect enrichment of CINP or NAPRT1 mRNAs in anti-V5 NSUN2 immunoprecipitates.
To validate the NSUN2 target RNAs identified by Aza-IP, we used short interfering RNA (siRNA) to knock down NSUN2 expression ( Fig. 4c) and then tested the location and extent of methylation on selected candidate target RNAs by conventional RNA bisulfite sequencing (Fig. 4d) . Here, we tested RNAs at the top (tRNA), middle (RPPH1) and bottom (SCARNA2 and VTRNA1-1) of our enrichment results. In control siRNA-treated HeLa cells, all tested RNA candidates displayed a methylation (cytosine retention) at the precise site(s) predicted by the Aza-IP transversion, but not at other flanking cytosines. We noted a marked diminishment or elimination of methylation at these sites in NSUN2 siRNA-expressing HeLa cells, validating the involvement of NSUN2 in target methylation (Fig. 4d) .
For several reasons, we suggest that diminishment rather than elimination in tRNA Gly methylation is predicted. Our protocol analyzes methylation at day 6, whereas NSUN2 protein knockdown via siRNA requires several days to reach >90% reduction; also tRNAs are long lived (~30-60 h), so those tRNAs made 2 days prior will still be largely present and methylated. Also, tRNAs, given their exceptional enrichment in Aza-IP, may be preferred by NSUN2 over the ncRNAs and may compete more effectively for the remaining NSUN2 pool. Regardless, these siRNA experiments validate the conclusions of the Aza-IP analysis.
The NSUN2 candidate ncRNA targets identified here include RNAs with central functions in the processing, folding and modification of other ncRNAs (RPPH1, Y RNA, SCARNA2), RNAs important for protein synthesis and trafficking (5S rRNA and 7SL RNA) and RNAs involved in multidrug resistance and other processes (Vault RNAs) 29, 30 . Notably, all of the NSUN2 targets revealed by Aza-IP are either transcribed by RNA Pol III 29 in the nucleolus (SCARNA2 excepted 30 ), or function in the nucleolus (SCARNA2) 30 , where NSUN2 is known to reside 12, 31 . The biological functions of RNA methylation at these sites remain to be explored, but they could affect RNA structure, association with ribonucleoprotein complexes, or complex activity. Taken together, our work greatly increases the set of target site candidates for NSUN2 that should be considered as possible contributors to enzyme function, including in pathologies related to cancer, stem cells and intellectual disability 12,14-17 .
Comparisons of our NSUN2 data sets to the recent RNA bisulfite sequencing (RBS-seq, with ABI sequencing platform) data set from HeLa cells 2 reveals high overlap, with the minor deviations likely resulting from the high filtering thresholds used in the RBS-seq method. Going forward, we envision Aza-IP and RBS-seq as complementary approaches. However, as Aza-IP enriches target RNAs (revealing low-copy RNAs), identifies only direct targets, and reveals the precise methylation sites in these targets (even in situations of m 5 C-RNA methyltransferase redundancy and/or low methylation penetrance), we intend to apply Aza-IP to discover new m 5 C-RNA methyltransferase targets and to validate these using focused RBS-seq or other approaches. Finally, additional mechanism-based 'adduct-IP' trapping techniques (using other nucleotide analogs 32 ) may help identify the targets of other RNA-modifying enzymes.
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We thank C. Clapier (hDNMT2 protein expression and purification), K. Rai oNLINe MeTHoDS DNMT2/DsRed Aza-IP experimental design and data analysis. Expression vector construction. Total RNA was extracted from HeLa cells using Trizol reagent (Invitrogen) and first-strand cDNA synthesis was performed with SuperScript III First-Strand Synthesis System (Invitrogen), using the Oligo(dT) (Invitrogen), according to the manufacturer's protocol. A DNMT2 clone (or DsRed) bearing a V5 tag was obtained by PCR from the HeLa cDNA (for hDNMT2), or from a DsRed plasmid (Clontech) as templates, using specific primer sets in a two-step PCR format. The primer sets ( Supplementary  Table 2 ) replaced the first (ATG) codon with an XhoI restriction site, and inserted the Kozak consensus sequence containing the start codon (CACCATGG), and the sequence corresponding to the V5 tag (GGTAAG CCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG) at the 5′ end of the amplicons. The primers also placed a BamHI restriction site at the 3′ end of these amplicons, right after the stop codon. Validated PCR products were double digested with XhoI and BamHI enzymes and were cloned into the multiple cloning sites of the pPR-lentiviral plasmid (a gift from V. Planelles, Professor of Pathology at University of Utah).
Virus production and titration. The expression vectors (hDNMT2 and DsRed) were used to produce viral particles via transfection. The expression (transfer) plasmids were mixed with packaging and VSVG envelope plasmids (gifts from V. Planelles) and transfected into the HEK-293-FT cells (Invitrogen) using polyethyleneimine (Polysciences). The viral particles were then harvested, concentrated by ultracentrifugation and titrated on HeLa cells using the EGFP marker (which exists on pPR-lentiviral plasmid backbone) by flow-cytometry. Expression of the V5-tagged transgenes was checked by western blotting of the protein extracted from the infected HeLa cells using anti-V5 antibody (Invitrogen). The concentrated viral particles were stored at −80 °C until used.
Lentiviral infection. A day before infection, 20 100-mm plates per experiment (e.g., hDNMT2 and DsRed) were each seeded with 2 million HeLa cells. 24 h later the proper amount of the titered virus, calculated to give ~100% infection rate, were mixed with 6 ml of DMEM media (Invitrogen) supplemented with 10% FBS and 4 µg/ml (final concentration) Polybrene (Millipore) and added to each plate. 12 h post infection, the media was removed and cells from all 20 plates were washed with 1× PBS and trypsinized using TrypLE Express (Invitrogen), and then were pooled and dispensed into fifteen 150 mm plates.
5-Azacytidine treatment. After 6 h the media of each plate was replaced with freshly prepared 5-Azacytidine containing DMEM media (final concentration of 3 µM). To prepare, 5-Azacytidine powder (Sigma) was dissolved in DMEM media to the concentration of 300 µM (100×), filtered and used to make the 1× (final concentration of 3 µM 5-Azacytidine) DMEM media supplemented with 10% FBS.
Preparing the pre-clearing beads. For each experiment, 750 µl of Dynabeads Pan Mouse IgG (Invitrogen) were washed in 1 ml of RIPA buffer (50 mM Tris PH 7.5, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA, 150 mM NaCl + Protease Inhibitor cocktail) supplemented with 5 mg/ml protease free bovine serum albumin (BSA) (Sigma) three times, 2 min each, and re-suspended in 1.5 ml of RIPA buffer + BSA + 30 µl of RNasIN (Promega).
Preparing the antibody coated beads. For each experiment, 1.5 ml of the Dynabeads Pan Mouse IgG were split into two 1.5 ml tubes (750 µl each) and washed with 1 ml of RIPA buffer + BSA three times, 2 min each. Next the beads of each tube were re-suspended in 1.5 ml of RIPA buffer + BSA + 45 µg of the mouse anti-V5 tag antibody (Invitrogen) and incubated at room temperature, rotating for 2 h. The beads of each tube were then washed with 1 ml of RIPA buffer + BSA three times, 2 min each, and were re-suspended in 1.2 ml of RIPA buffer + BSA + 25 µl of RNasIN.
Cell lysis and solubilization. 12 h after 5-Azacytidine treatment, cells were washed with 1× PBS and trypsinized and quenched with complete DMEM media. Then the contents of each group of three 150 mm plates were pooled in a single 15 ml conical tube, spun at 2,000 r.p.m. (~650g) at 4 °C for 5 min. Next, 2.5 ml of 1× PBS were added to the cells of each of the 15 ml conical tubes (5 conical tubes per experiment). Then the cells were re-suspended and all of them were pooled in a single 15 ml conical tube, spun at 2,000 r.p.m. at 4 °C for 5 min and the supernatant was discarded. Cells were then lysed in RIPA buffer (total volume of 6 ml) supplemented with 30 µl of RNaseIN, by pipetting up and down several times to get a homogenous lysate. The 6 ml cell lysate was then subjected to sonication, using Misonix Sonicator XL2020, 6 times for 30 s (at setting #4 (0.9 ON time/0.1 OFF time)) followed by 30 s on ice at each round. After sonication another 6 ml of the RIPA buffer was added to the lysate (total of 12 ml) and the diluted lysate was dispensed into twelve 1.5 ml Eppendorf tubes, 1ml each and spun at 14,000 r.p.m. (~21,000g) at 4 °C for 10 min. The cleared lysates were then transferred to clean 1.5 ml tubes and kept on ice.
Immunoprecipitation. For each 1 ml of the lysate (in one 1.5 ml tube), 125 µl of the pre-clearing beads were added and incubated at room temperature, rotating. After 2 h, using a magnetic stand, the supernatant of each tube was removed and transferred to a new 1.5 ml tube. Next, 200 µl of the re-suspended antibody coated beads were added to each of the tubes and the mixtures were incubated at room temperature, rotating. After 4 h the supernatant of each tube was removed and discarded and the beads were washed with 850 µl of RIPA + BSA + RNaseIN, 3 times, 5 min each at room temperature. Then the beads were re-suspended in 500 µl of RIPA + BSA + RNaseIN and were transferred to a 0.5 ml clean Eppendorf tube. The supernatant of each tube was then removed and discarded.
RNA fragmentation. For each of the 12 small (0.5 ml) Eppendorf tubes, 7.5 µl of the RNA fragmentation reagent (Ambion) was mixed with 67.5 µl of RNase free ddH 2 O (Ambion) in one tube (total of 75 µl per tube) and in another tube 7.5 µl of the fragmentation stop solution (Ambion) was mixed with 7.5 µl of RNase free ddH 2 O (total of 15 µl per tube). For the fragmentation, 75 µl of the diluted RNA fragmentation reagent was added to beads of each tube, followed by incubating the tubes at 94 °C for exactly 5 min in a thermocycler, chilled on ice for 1 min, and then the fragmentation was stopped by adding 15 µl of the diluted stop solution.
Ethanol precipitation and RNA extraction. After fragmentation, the supernatant of all small tubes was removed and pooled in a clean 1.5 ml tube (total of 1080 µl). Next 40 µl of the 15 mg/ml GlycoBlue (Ambion) and 104 µl of 3 M Sodium Acetate (Ambion) were mixed with the fragmented RNA and the mixture was split into three 1.5 ml tubes (346 µl each). Then 865 µl absolute ethanol was added to each tube and the tubes were incubated at −80 °C overnight, and spun at maximum speed at 4 °C for 20 min. The pellets were then washed once with 1 ml of 70% ice cold ethanol, air dried and dissolved in total of 40 µl RNase free ddH 2 O (for all three of the tubes per experiment) and pooled in a single tube. Next 1 ml of Trizol reagent was added and the RNA was extracted according to the manufacturer's protocol.
Library preparation and high-throughput sequencing. Illumina's directional mRNA-Seq sample preparation protocol was used to prepare the libraries, by ligating the adapters to the fragmented RNAs followed by reverse transcription, PCR and sample clean-up using AMPure beads (Beckman Coulter Genomics). The libraries were then subjected to 50-cycle single-end highthroughput sequencing using Illumina's HiSeq 2000 sequencing system.
Computational analytical methods. Sequenced reads were aligned to the H. sapiens Feb 2009 genome build plus all known and theoretical splice junctions derived from Ensembl transcripts (see "MakeTranscriptome" application from open source USeq package 33 ). Sequence alignments was performed using the commercial Novoalign package (http://www.novocraft.com) with options to allow gaps and mismatches, reporting 18 bp or larger inserts and reporting all of the reads mapped to the repeats and generating SAM-formatted alignment files. To assess the enriched regions and also making the BAM/BAI files for visualization the "RNASeq" application of the USeq package was used. The Integrative Genomics Viewer (IGV) 34 was used to visualize the alignment files, inspect the mapped reads at base pair resolution and obtain the base distribution reports at desired locations (e.g., C38 position of DNMT2 target tRNAs). The data sets from mRNA sequencing of the input samples were processed via the same pipeline. For calculating the total number of reads mapped to tRNA loci in Aza-IP data sets, applications from the open source Biotoolbox (http://code.google.com/p/biotoolbox) were used. First, the total number of reads mapped to individual annotated tRNAs was calculated and then the numbers for each tRNA types were summed manually to calculate the total number of reads belonging to a particular tRNA type. The total numbers were then normalized to the total number of mapped reads for each dataset. The fold enrichment values for all tRNAs were calculated by dividing the RPKM npg cloned using TOPO TA Cloning Kit (Invitrogen) and the resulting plasmids purified from several clones were sequenced. The sequences were aligned with the corresponding tRNA sequences and the maintained cytosines (representing methylated cytosines) are depicted in the figures as closed circles.
